No Data
No Data
Blueprint Medicines to Report Third Quarter 2024 Financial Results on Wednesday, October 30, 2024
Morgan Stanley Maintains Blueprint Medicines(BPMC.US) With Hold Rating, Maintains Target Price $120
S&P 500 Futures Decline In Premarket Trading; GXO Logistics, Celsius Holdings Lead
Barclays Maintains Blueprint Medicines(BPMC.US) With Hold Rating, Maintains Target Price $105
Blueprint Medicines Insider Sold Shares Worth $324,500, According to a Recent SEC Filing
Investing in Blueprint Medicines (NASDAQ:BPMC) a Year Ago Would Have Delivered You a 74% Gain
No Data
No Data